Regulus Therapeutics Inc.
NASDAQ:RGLS
Overview | Financials
Company Name | Regulus Therapeutics Inc. |
Symbol | RGLS |
Currency | USD |
Price | 1.54 |
Market Cap | 100,870,154 |
Dividend Yield | 0% |
52-week-range | 1.08 - 3.79 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. Joseph P. Hagan M.B.A. |
Website | https://www.regulusrx.com |
An error occurred while fetching data.
About Regulus Therapeutics Inc.
Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD